Résultats de la recherche - 3 results
Early high antibody-titre convalescent plasma for hospitalised COVID-19 patients: DAWn-plasma.
Maes; Alexander Schauwvlieghe; Laurens Liesenborghs; Ann Belmans; Peter Verhamme; Geert Meyfroidt; DAWn-plasma investigators Source: Eur Respir J (2021) Abstract: BACKGROUND: Several randomised clinical ...
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the DAWn-Plasma trial.
BACKGROUND: The COVID-19 pandemic has imposed an enormous burden on health care systems around the world. In the past, the administration of convalescent plasma of patients having recovered from SARS and severe ...
SARS-CoV-2 neutralising antibody testing in Europe: towards harmonisation of neutralising antibody titres for better use of convalescent plasma and comparability of trial data.
compared the performance of SARS-CoV-2 neutralising antibody testing between 12 European laboratories involved in convalescent plasma trials. Raw titres differed almost 100-fold differences between ...